Keryx Biopharmaceuticals Inc. (KERX) Lifted to “Strong-Buy” at Vetr Inc.
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) was upgraded by investment analysts at Vetr from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday. The firm currently has a $5.93 price objective on the biopharmaceutical company’s stock. Vetr‘s target price would suggest a potential upside of 19.56% from the stock’s previous close.
A number of other equities analysts also recently commented on KERX. Zacks Investment Research downgraded Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 3rd. FBR & Co reiterated a “buy” rating and set a $13.00 price objective on shares of Keryx Biopharmaceuticals in a research report on Monday, July 25th. Brean Capital downgraded Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 2nd. Stifel Nicolaus downgraded Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 2nd. Finally, Maxim Group reiterated a “buy” rating and set a $9.00 price objective (up from $7.00) on shares of Keryx Biopharmaceuticals in a research report on Friday, July 8th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $8.44.
Keryx Biopharmaceuticals (NASDAQ:KERX) traded down 8.49% during trading on Wednesday, reaching $4.96. The company’s stock had a trading volume of 2,699,019 shares. Keryx Biopharmaceuticals has a 52 week low of $2.80 and a 52 week high of $7.80. The firm’s market capitalization is $525.24 million. The firm has a 50-day moving average price of $4.84 and a 200-day moving average price of $5.46.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/keryx-biopharmaceuticals-inc-kerx-lifted-to-strong-buy-at-vetr-inc-2.html
Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.14. Keryx Biopharmaceuticals had a negative net margin of 590.50% and a negative return on equity of 172.04%. The company earned $9.30 million during the quarter, compared to analyst estimates of $8.60 million. During the same quarter in the previous year, the firm earned ($0.26) earnings per share. The business’s revenue was up 272.0% on a year-over-year basis. On average, equities analysts anticipate that Keryx Biopharmaceuticals will post ($1.24) EPS for the current fiscal year.
In other news, CFO Scott A. Holmes sold 4,935 shares of the stock in a transaction on Friday, July 29th. The stock was sold at an average price of $7.36, for a total transaction of $36,321.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.08% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Alpine Partners VI LLC acquired a new stake in Keryx Biopharmaceuticals during the second quarter worth about $110,000. Trexquant Investment LP acquired a new stake in Keryx Biopharmaceuticals during the second quarter worth about $115,000. Cambridge Investment Research Advisors Inc. raised its stake in Keryx Biopharmaceuticals by 38.2% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 18,100 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 5,000 shares during the last quarter. LMR Partners LLP acquired a new stake in Keryx Biopharmaceuticals during the second quarter worth about $125,000. Finally, Stifel Financial Corp acquired a new stake in Keryx Biopharmaceuticals during the second quarter worth about $170,000. Institutional investors own 61.13% of the company’s stock.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.